RemeGen Co., Ltd. Announces New H Shares Placement to Raise HK$806 Million

RemeGen Co. Ltd. Class H ( (HK:9995) ) has issued an announcement.

RemeGen Co., Ltd. announced the placement of new H shares under a general mandate, with the aim of raising approximately HK$806.36 million in gross proceeds. The net proceeds, estimated at HK$796 million, will be used to further invest in the research and development of Telitacicept and for general corporate purposes. This strategic move represents around 10.02% of the existing H shares and 3.49% of the total issued shares, potentially enhancing the company’s market position and supporting its growth initiatives. The placement will be conducted by placing agents to a minimum of six independent investors, subject to certain conditions and termination rights.

The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.

More about RemeGen Co. Ltd. Class H

RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biotechnology industry. The company focuses on the research and development of innovative drugs, with a particular emphasis on its core product, Telitacicept (RC18), which targets conditions such as Myasthenia Gravis and Membranous Nephritis.

Average Trading Volume: 9,028,785

Technical Sentiment Signal: Buy

Current Market Cap: HK$26.15B

See more data about 9995 stock on TipRanks’ Stock Analysis page.